Power Metallic’s (TSX-V: PNPN | OTCQB: PNPNF) Strategic Appointment Signals Major Paradigm Shift Ahead – More Stocks InsidePower Metallic Mines Inc. (TSX-V: PNPN; OTCQB: PNPNF; Frankfurt: IVV) today announced the appointment of Seamus O’Regan Jr., Canada’s former Minister of Energy & Natural Resources, to its Board of Directors.
Allarity Therapeutics Announces Changes to Board of Directors TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company’s Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity’s development over the past two years.
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment - Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months- Initiated utilization of share repurchase program- Cash and restricted cash balance of approximately $27 million at end of Q1 2025, reinforcing financial stability
Allarity Therapeutics Announces Dismissal of Securities Class Action LawsuitBoston (February 26, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced that the securities class action lawsuit in the United States District Court for the Southern District of New York referenced in the Company’s Form 10-Q filing on November 11, 2024, has been dismissed in whole against all defendants.
